Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ulla Niskala
Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
Advances in Therapy
Medicine
Pharmacology
Related publications
Cladribine for Highly Active Relapsing Multiple Sclerosis
Prescriber
Pharmacology
Pnd26 - Cost Implications of a Novel Weight Dosed Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd65 - Cost-Effectiveness Analysis of Drugs Used for the Treatment of Highly Active Relapsing Multiple Sclerosis in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd27 - Cost Implications in the Selection of First Line Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd62 - Cost-Effectiveness of Cladribine Tablets in the Treatment of Patients With Highly Active Relapsing Multiple Sclerosis in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis
JAMA Neurology
Neurology
Pnd29 - Long Range Simulation of the Cost Burden of Difference Treatment Sequences Approved for the Treatment of Highly Active Relapsing Multiple Sclerosis in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd73 - The Impact of Modelling Subsequent Treatment on Estimates of Cost-Effectiveness: An Analysis of Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Emerging Therapies for Relapsing Multiple Sclerosis
Archives of Neurology
